Abstract: Objective To investigate the expressions of gliomaassociated oncogene 1（Gli1） in molecular subtypes of breast cancer and the relevant significance.
MethodsThe expression of Gli1 was measured in breast cancer tissues by immunohistochemistry. The relationship between Gli1 and the expressions of estrogen receptor （ER）， progesterone receptor （PR）， human epidermal growth factor receptor2 （HER-2） and Ki67 was analyzed. Furthermore， the differences of Gli1 expression among different Ki67 related molecular subtypes were discussed. Results We found statistically significant differences in the distribution of the Gli1 expression between different levels of ER， Ki-67 and TNM stage （P＜0.05）. The Gli1positive rates of luminal A subtype， luminal B subtype， HER-2 enriched subtype and basal-like subtype were 51.35％， 81.25％， 88.24％ and 96.15％， respectively. Compared with other subtypes， the positive rate of Gli1 expression in luminal A subtype was lowest and the expression of Gli1 was mainly lowlevel with significant difference （P＜0.05）. Conclusion The Gli1 in luminal A type was mainly lowexpressed， and it may be used as a diagnostic evidence for single endocrine therapy. High expression of Gli1 mainly existed in luminal B subtype， HER-2 enriched subtype and basallike subtype， which was a possible potential therapeutic target for basal-like subtype.